Skip to main content

Table 2 Perioperative period

From: Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study

Medications

NEO (n = 175)

SUG (n = 175)

P value

Intraoperative period

 Intravenous anesthesia, n (%)

62 (35.4)

56 (32)

0.572

 Inhalational anesthesia, n (%)

 

• Sevoflurane, n (%)

65 (37.1)

58 (33.1)

0.502

• Desflurane, n (%)

48 (27.4)

61 (34.9)

0.166

 Fentanyl, n (%)

67 (38.3)

72 (41.1)

0.662

 Remifentanil, n (%)

86 (49.1)

92 (52.6)

0.593

 Ketamine, n (%)

20 (11.4)

15 (8.6)

0.476

 Paracetamol, n (%)

153 (87.4)

159 (90.9)

0.391

 Morphine, n (%)

27 (15.4)

25 (14.3)

0.881

 Tramadol, n (%)

99 (56.6.4)

92(52.6.3)

0.520

 Vasoactive drugs, n (%)

38 (21.7)

35 (20)

0.793

 Droperidol, n (%)

39 (22.3.9)

42 (24)

0.800

 Ondansetron, n (%)

149 (85.1)

141 (80.6)

0.321

 Clonidine, n (%)

15 (8.6)

9 (5.1)

0.290

 Pethidine, n (%)

10 (5.7)

7 (4.0)

0.620

 Cisatracurium, mg [IQR]

36.9 [21.8-70.1]

0.0 [0.0-0.0]

< 0.001

 Rocuronium, mg [IQR]

0.0 [0.0-0.0]

110.0 [60.0-220.0]

< 0.001

 Atropine (%)

141 (80.6)

0.0 (0.0)

< 0.001

 Neostigmine (%)

175.0 (100)

0.0 (0.0)

< 0.001

 Neostigmine, μg/kg

29.9 [12.2-67.4]

0.0 [0.0-0.0]

< 0.001

 Sugammadex 2 mg/kg (%)

0 (0.0)

101 (57.7)

< 0.001

 Sugammadex 4 mg/kg (%)

0 (0.0)

74 (42.3)

< 0.001

 Fluid total, ml

2100 [1800-2500]

2100 [1700-2400]

0.168

 Surgery, min [IQR]

185 [155-237.5]

180 [150-225]

0.116

 Anesthesia, min [IQR]

235 [210-292.5]

240 [205-285]

0.589

Postoperative period

 SpO2 at T15, %

99 [98-99]

99 [98-100]

0.117

 HR at T15, beats/min [IQR]

81.0 [71-91]

82 [72.5-92.5]

0.271

 SBP at T15, mmHg [IQR]

140.0 [130-154.5]

145 [128.5-157.5]

0.503

 DBP at T15, mmHg [IQR]

80.0 [71.0-87.5.5]

79 [70.0-88.0]

0.348

 pH at T15 [IQR]

7.36 [7.33-7.4]

7.36 [7.33-7.39]

0.671

 PaO2 at T15, mmHg [IQR]

88.6 [76-103.2]

89.2 [79.5-101.4]

0.253

 PaCO2 at T15, mmHg [IQR]

39.6 [36.2-42.4]

39.7 [36.4-43.6]

0.207

 Pain NRS>3 at T15, n (%)

18 (10.3)

14 (8.0)

0.579

 PONV NRS>3 at T15, n (%)

13 (7.4)

8 (4.6)

0.368

 Hypoxemia, n (%)

11 (6.3)

1 (0.6)

0.006

 Antihypertensive drugs, n (%)

16 (9.1)

9 (5.1)

0.212

 PACU stay, min [IQR]

90 [60-105]

70 [60.0-90.0]

< 0.001

 ICU admission, n (%)

14 [8.0]

1 [0.6]

0.001

  1. NMB neuromuscular block, NEO group of patients receiving neostigmine for reversal of cisatracurium-induced NMB, SUG group of patients receiving sugammadex for reversal of rocuronium-induced NMB; vasoactive drugs: repeated administration of etilefrine or ephedrine, or dopamine infusion; surgery: time from skin incision to the placement of the last suture; anesthesia: time from tracheal intubation to tracheal extubation; PACU (post-anesthesia care unit): time from PACU admission to discharge to the surgical ward, ICU intensive care unit, SpO2 peripheral arterial blood oxygen saturation, PaO2 arterial partial pressure of oxygen, PaCO2 arterial partial pressure of carbon dioxide, HR heart rate, SBP systolic arterial blood pressure, DBP diastolic arterial blood pressure, T15 15 min after tracheal extubation, NRS numeric rating scale, PONV postoperative nausea and vomiting, hypoxemia oxygen desaturation (SaO2<90%) requiring treatment; antihypertensive drugs: clonidine, urapidil; amlodipine, labetalol; diltiazem. Data are expressed as median [interquartile range, IQR] or number, n (%)